$ cat ./records/gates-foundation-pledges-1-6-billion-to-gavi-and-150-million-to-c-2020.txt
Gates Foundation Pledges $1.6 Billion to Gavi and $150 Million to COVAX Vaccine Equity Facility
[RECORD.TXT] · cat --full
At the Global Vaccine Summit hosted by UK Prime Minister Boris Johnson, the Gates Foundation announced a five-year, $1.6 billion commitment to Gavi, the Vaccine Alliance, covering 2021–2025. Separately, the foundation pledged $150 million specifically to Gavi's COVID-19 Vaccine Advance Market Commitment (COVAX AMC) to finance COVID-19 vaccine procurement for 92 lower-income countries. The COVAX pledge was among the earliest major philanthropic contributions to the vaccine equity mechanism that would eventually deliver more than one billion doses to lower-income nations.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Announces Additional $50 Million to COVAX and $20 Million to CEPI
Next →
Gates Foundation, Wellcome, and Mastercard Launch $125 Million COVID-19 Therapeutics Accelerator
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.